Improving radical treatment through MRI evaluation of pelvic sigmoid cancers
IRAS Number: 137312
CPMS ID: 17006
ClinicalTrials.gov ID: NCT02222844
Trial Start Date: Aug-14
Recruitment End Date: Dec-26
Trial End date: Dec-29
We want to test whether the information from an MRI gives more accurate information than a CT scan about tumours in the sigmoid colon. This trial will also enable us to find out whether having an MRI scan prior to surgery could improve the treatment choices offered to patients.
A randomised phase II multicentre trial, IMPRESS will determine whether the use of MRI imaging in staging sigmoid cancers results in a change to the treatment plan by identifying more high risk tumours compared to those patients who were staged using CT imaging. The proposed intervention will be additional radiological and pathological assessment and the reporting of supplementary diagnostic information which would not otherwise have been available. This may affect treatment according to local MDT protocols and also affect the provision of prognostic information to patients in subsequent discussions.
Patients with suspected or proven sigmoid colon adenocarcinoma, eligible for curative treatment whose MRI can be reviewed prior to surgery and has no decision regarding radical treatment are eligible. Patient are randomised to the control arm which the standard care of preoperative CT imaging and subsequent discussion by the Multidisciplinary Team or the interventional arm which has the additional use of MRI imaging and subsequent discussion by the Multidisciplinary Team. Patients are followed up at 1 and 3 years together with QoL questionnaires.
The IMPRESS trial is open to new sites.
Please fill in the form below if you would like further information or have any questions about any aspect of the trial.
